Drug intervention trials in sepsis [3]

Lancet

Volumn 364, Issue 9433, 2004, Pages 498-

  Ritter, Cristiane ^a   Andrades, Michael ^b   Reinke, Adalisa ^a   Moreira, José Cláudio F ^b   Dal Pizzol, Felipe ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIINFECTIVE AGENT; ANTIOXIDANT; DEFEROXAMINE; INTERLEUKIN 18 BINDING PROTEIN; SUPEROXIDE DISMUTASE;

ANTIMICROBIAL THERAPY; CYTOKINE PRODUCTION; DISEASE MARKER; DISEASE SEVERITY; ENZYME BLOOD LEVEL; EXPERIMENTAL INFECTION; EXPERIMENTAL MOUSE; INFECTION RISK; LETTER; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SEPSIS; SURVIVAL; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 4043128085     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16799-8     Document Type: Letter

References (4)

1. Polderman KH, Girbes ARJ. Drug intervention trials in sepsis: divergent results. Lancet. 363:2004;1721-1723
2. Remick DG, Bolgos GE, Siddiqui J. Inflammatory status in sepsis alters efficacy of interleukin-18 binding protein therapy. Crit Care Med. 31:2003;2096-2101
3. Ritter C, Andrades ME, Frota MLC, et al. Oxidative parameters and mortality in sepsis induced by cecal ligation and perforation. Int Care Med. 29:2003;1782-1789
4. Ritter C, Andrades ME, Reinke A, Menna-Barreto S, Moreira JCF, Dal-Pizzol F. Treatment with N-acetylcysteine plus deferoxamine protects rats against oxidative stress and improves survival in sepsis. Crit Care Med. 32:2004;342-349